Pharma News
The Regulatory Consequences of the Mifepristone Case: Q&A with Meg Alexander, Chief Strategy Officer at Ovid Therapeutics
![](https://meefro.com/wp-content/uploads/2024/03/The-Regulatory-Consequences-of-the-Mifepristone-Case-QampA-with-Meg-780x470.png)
Alexander discusses the broader implications the case could have on FDA’s ability to regulate the industry.
Source link
#Regulatory #Consequences #Mifepristone #Case #QampA #Meg #Alexander #Chief #Strategy #Officer #Ovid #Therapeutics